John B Tew

US Patent:

8003385, Aug 23, 2011

Filed:

Feb 17, 2010

Appl. No.:

12/707563

Inventors:

Selva Sukumar - Berkeley CA, US
Mohey Eldin M. El Shikh - Richmond VA, US
John G. Tew - Mechanicsville VA, US
Donald Drake, III - Orlando FL, US
Luis Mosquera - Oviedo FL, US
Conan Li - Los Altos CA, US
Anatoly M. Kachurin - Orlando FL, US
Russell Higbee - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US
Eric Mishkin - Winter Springs FL, US
William L. Warren - Orlando FL, US

Assignee:

Sanofi Pasteur Vax Design Corp. - Orlando FL

International Classification:

C12N 5/06
C12N 5/02

US Classification:

435326, 435375, 435377

Abstract:

The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

US Patent:

8003387, Aug 23, 2011

Filed:

Dec 21, 2006

Appl. No.:

11/642938

Inventors:

Selva Sukumar - Berkeley CA, US
Mohey Eldin M. El Shikh - Richmond VA, US
John G. Tew - Mechanicsville VA, US
Donald Drake, III - Orlando FL, US
Luis Mosquera - Oviedo FL, US
Eric Mishkin - Winter Springs FL, US
Anatoly M. Kachurin - Orlando FL, US
Russell Higbee - Orlando FL, US
Conan Li - Los Altos CA, US
William L. Warren - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US

Assignee:

Sanofi Pasteur Vaxdesign Corp. - Orlando FL

International Classification:

C12N 5/08
C12N 5/00
C12N 5/02

US Classification:

435373, 435375, 435377

Abstract:

The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

US Patent:

8247226, Aug 21, 2012

Filed:

Jun 23, 2011

Appl. No.:

13/167115

Inventors:

Selva Sukumar - Berkeley CA, US
Mohey Eldin M. El Shikh - Richmond VA, US
John G. Tew - Mechanicsville VA, US
Donald Drake, III - Orlando FL, US
Luis Mosquera - Oviedo FL, US
Conan Li - Los Altos CA, US
Anatoly M. Kachurin - Orlando FL, US
Russell Higbee - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US
Eric Mishkin - Winter Springs FL, US
William L. Warren - Orlando FL, US

Assignee:

Sanofi Pasteur Vaxdesign Corp. - Orlando FL

International Classification:

C12N 5/00
C12N 5/02

US Classification:

435375, 435382, 435404

Abstract:

The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

US Patent:

20110269176, Nov 3, 2011

Filed:

Jun 23, 2011

Appl. No.:

13/167131

Inventors:

Selva SUKUMAR - Berkeley CA, US
Mohey Eldin M. EL SHIKH - Richmond VA, US
John G. TEW - Mechanicsville VA, US
Donald DRAKE, III - Orlando FL, US
Luis MOSQUERA - Oviedo FL, US
Eric MISHKIN - Winter Springs FL, US
Anatoly M. KACHURIN - Orlando FL, US
Russell HIGBEE - Orlando FL, US
Conan LI - Los Altos CA, US
William L. WARREN - Orlando FL, US
Heather FAHLENKAMP - Cleveland OK, US

Assignee:

SANOFI PASTEUR VAXDESIGN CORPORATION - Orlando FL

International Classification:

C12Q 1/18

US Classification:

435 32

Abstract:

The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.